Anti-sIL7R mAb

About Autoimmunity Biosolutions

Autoimmunity BioSolutions is pioneering a genetically-targeted approach to treat refractory autoimmune diseases by neutralizing the soluble IL-7 receptor (sIL7R). The company's foundational hypothesis is that a common SNP (rs6897932) drives sIL7R overexpression, which is a key driver of pathogenesis and non-response in approximately 30-50% of patients with conditions like rheumatoid arthritis, lupus, and type 1 diabetes. ABS is developing a monoclonal antibody against sIL7R, aiming to 'reset' immune function without broad immunosuppression. This positions the company to address a significant unmet need in autoimmune care through a personalized medicine lens.

Therapeutic Areas